Insmed Inc (INSM)vsProMIS Neurosciences Inc. (PMN)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
PMN
ProMIS Neurosciences Inc.
$17.43
-1.91%
HEALTHCARE · Cap: $37.88M
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 8021368% more annual revenue ($606.42M vs $7,560). PMN leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
PMN
Avoid21
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
No standout strengths identified
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : PMN
PMN has a balanced fundamental profile.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : PMN
The primary concerns for PMN are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while PMN is a value play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
PMN generates stronger free cash flow (-10M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 21/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
ProMIS Neurosciences Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
ProMIS Neurosciences Inc. is an innovative biotechnology company focused on developing transformative therapeutic solutions for neurodegenerative diseases, particularly Alzheimer's and amyotrophic lateral sclerosis (ALS). Leveraging its proprietary protein engineering platform, the firm identifies and targets misfolded proteins linked to these debilitating conditions, delivering the potential for groundbreaking treatments with enhanced safety profiles. With a diverse pipeline of drug candidates progressing through various stages of development, ProMIS stands at the forefront of neurotherapeutic advancements, poised to address significant unmet medical needs and exert a meaningful impact within the biopharmaceutical landscape.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?